Autonomix Medical (NASDAQ: AMIX) recently demonstrated the effectiveness of their proprietary catheter-based sensing technology in a preclinical study involving the renal artery. The study aimed to evaluate the technology’s ability to sense and target individual nerves surrounding the renal artery using epivascular injections of ethanol.
During the study, Autonomix Medical’s catheter-based sensing technology was able to successfully capture the down-regulated nerve signal of the treated nerve from within the renal artery. The technology also detected the return to normal signal post-ethanol treatment, marking a significant milestone for the company.
The successful demonstration of the technology’s capabilities has the potential to revolutionize treatment options for various medical conditions by accurately sensing and targeting individual nerves surrounding the renal artery. By leveraging their innovative catheter-based sensing technology, Autonomix Medical aims to further advance the field of medical research and provide new solutions for patients in need. The company’s commitment to developing cutting-edge medical technologies positions them as a leading player in the industry.
